|
|
|
|
|
APO010APO010, also called mega-FasLigand, is a recombinant fusion protein derived from the pro-apoptotic human Fas ligand (FasL) protein, a member of the TNF protein family. APO010 targets Fas (also known as CD95 or Apo1) receptors on the surface of cancer cells, and induces cell death via a mechanism of cell suicide termed apoptosis. The product is a fusion protein consisting of three human FasL extracellular domains linked to a protein backbone comprising the dimer-forming collagen domain of human adiponectin. The recombinant human protein product is produced for experimental and clinical use as a glycoprotein in mammalian cells (Chinese hamster ovary cell ("CHO")) using a GMP compliant manufacturing process developed by Apoxis, now TopoTarget Switzerland S.A.Phase I studies of APO010 in patients with advanced cancers
A Phase I dose-escalation study of APO010 up to 35 patients with untreatable advanced or refractory solid tumours has been initiated in order to establish the safety and tolerability and maximum tolerated dose in man. In addition, pharmacokinetics, immunogenicity and preliminary signs of anti-cancer activity is evaluated. Useful links :
Therapeutic Areas
- Solid tumours and haematology
Science
- MegaLigandTM Technology
|
|
|
About Us
Cancer